NanoViricides, Inc. reported on the strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV (Respiratory Syncytial Virus). NV-387 Can Advance Directly into Phase II Human Clinical Trials for RSV Treatment: NV-387 is the active ingredient of NV-CoV-2, the Company's drug for the treatment of COVID and possibly long COVID. It is already in Phase 1a/1b human clinical trials for the evaluation of safety in healthy volunteers and of safety and preliminary efficacy in COVID patients as previously reported.

It is expected that NV-387 can be advanced into Phase II studies against RSV once the current Phase I studies of NV-CoV- 2 are completed. This will significantly speed up the development of the RSV drug, save costs, and improve return on investments (ROI). The Company cannot project exact dates for the regulatory activities in progressing its drug candidates because of the Company's significant dependence on external collaborators and consultants.

The Company is currently focused on advancing NV-CoV-2 through Phase I/II human clinical trials. NV-CoV-2 is the Company's nanoviricide drug candidate for COVID. NV-CoV- 2-R is another drug candidate for COVID that is made up of NV-CoV-1 with Remdesivir, an already approved drug, encapsulated within its polymeric micelles.

Remdesivir is developed by Gilead. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.